CoChat

Combined targeting of HER2 and VEGFR2 for effective treatment of HER2 -amplified breast cancer brain metastases

Open access

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Brain metastases are a serious obstacle in the treatment of patients with human epidermal growth factor receptor-2 ( HER2 )–amplified breast cancer. Although extracranial disease is controlled with HER2 inhibitors in the majority of patients, brain metastases often develop. Because these brain metastases do not respond to therapy, they are frequently the reason for treatment failure. We developed a mouse model of HER2 -amplified breast cancer brain metastasis using an orthotopic xenograft of BT474 cells. As seen in patients, the HER2 inhibitors trastuzumab and lapatinib controlled tumor progression in the breast but failed to contain tumor growth in the brain. We observed that the combination of a HER2 inhibitor with an anti–VEGF receptor-2 (VEGFR2) antibody significantly slows tumor growth in the brain, resulting in a striking survival benefit. This benefit appears largely due to an enhanced antiangiogenic effect: Combination therapy reduced both the total and functional microvascular density in the brain xenografts. In addition, the combination therapy led to a marked increase in necrosis of the brain lesions. Moreover, we observed even better antitumor activity after combining both trastuzumab and lapatinib with the anti-VEGFR2 antibody. This triple-drug combination prolonged the median overall survival fivefold compared with the control-treated group and twofold compared with either two-drug regimen. These findings support the clinical development of this three-drug regimen for the treatment of HER2 -amplified breast cancer brain metastases.

Overview

Integrity signals

Registry

Crossref · 10.1073/pnas.1216078109

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Research works printed but not linked: 4

  1. 10.1200/jco.2008.19.8481 · DOI · Paper page
  2. 10.1038/nrclinonc.2011.58 · DOI · Paper page
  3. 10.1038/416279b · DOI · Paper page
  4. 10.1038/nature10144 · DOI · Paper page

Cited by

See all 166

Metadata

Authors
Kodack, D. P., Chung, E., Yamashita, H., Incio, J., Duyverman, A. M. M. J., Song, Y., Farrar, C. T., Huang, Y., Ager, E., Kamoun, W., Goel, S., Snuderl, M., Lussiez, A., Hiddingh, L., Mahmood, S., Tannous, B. A., Eichler, A. F., Fukumura, D., Engelman, J. A., & Jain, R. K.
Affiliations
  • Harvard University (US)
  • Gwangju Institute of Science and Technology (KR)
  • Edwin L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology,
  • Department of Medicine,
  • Athinoula A. Martinos Center for Biomedical Imaging (US)
  • Department of Neurology, and
Venue
Proceedings of the National Academy of Sciences
Published
2012-09-26
Volume
109
Issue
45
Pages
E3119-27
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2085327953
Cited by
153
References
38
Citations by year
2026: 7 · 2025: 7 · 2024: 10 · 2023: 7 · 2022: 10 · 2021: 8 · 2020: 16 · 2019: 10 · 2018: 11 · 2017: 14 · 2016: 8 · 2015: 17 · 2014: 12 · 2013: 16
FWCI
11.60
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Funders
  • National Institute on Aging (K25AG029415)
  • National Cancer Institute (T32CA073479, R01CA096915, P01CA080124, R21CA155862, R01CA126642)
Topics
  • Health Sciences › Medicine › Oncology › Brain Metastases and Treatment
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords
HER2-amplified breast cancer, brain metastases, VEGFR2, trastuzumab, lapatinib, combination therapy, antiangiogenic activity, microvessel density, tumor necrosis, BT474 xenograft, orthotopic xenograft, overall survival
MeSH terms
Trastuzumab, Lapatinib, Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Blood Vessels, Brain Neoplasms, Breast Neoplasms, Diagnostic Imaging, Disease Models, Animal, Female, Gene Amplification, Humans, Killer Cells, Natural, Necrosis, Neovascularization, Pathologic, Quinazolines, Survival Analysis, Treatment Outcome, Cell Death, Erb-b2 Receptor Tyrosine Kinases, Xenograft Model Antitumor Assays, Receptors, Vascular Endothelial Growth Factor, Cell Proliferation, Mice, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combined targeting of HER2 and VEGFR2 for effective treatment of HER2 -amplified breast cancer brain metastases. https://app.cochat.ai/papers/10.1073/pnas.1216078109
The paper
Kodack, D. P., Chung, E., Yamashita, H., Incio, J., Duyverman, A. M. M. J., Song, Y., Farrar, C. T., Huang, Y., Ager, E., Kamoun, W., Goel, S., Snuderl, M., Lussiez, A., Hiddingh, L., Mahmood, S., Tannous, B. A., Eichler, A. F., Fukumura, D., Engelman, J. A., & Jain, R. K. (2012). Combined targeting of HER2 and VEGFR2 for effective treatment of HER2 -amplified breast cancer brain metastases. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1216078109

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.